Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Friday, April 26, 2024 | Back issues
Courthouse News Service Courthouse News Service

EpiPen antitrust

KANSAS CITY, Kan. — A federal judge allowed a class of EpiPen users to pursue antitrust claims against drugmaker Mylan, ruling they sufficiently showed the company, in cooperation with Pfizer, attempted to dominate the emergency allergy medication market and delay entry of a generic version.

Click here to read the ruling.

Categories / Briefs, Business, Health

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...